Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schwenkglenks

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 29, 2007
Simulation-based cost-utility analysis of population screening-based alendronate use in SwitzerlandM Schwenkglenks, K Lippuner
Medizinische Klinik (Munich, Germany : 1983)|February 11, 2000
[Economic evaluation of different treatment strategies in patients with stable angina pectoris or asymptomatic myocardial ischemia on basis of results from the Asymptomatic-Cardiac-Ischemia Pilot study (ACIP)]T D Szucs, M Schwenkglenks, W Rutishauser
Infection|September 22, 2009
Disparities in influenza vaccination coverage rates by target group in five European countries: trends over seven consecutive seasonsP R Blank, M Schwenkglenks, T D Szucs
Zeitschrift Fur Kardiologie|March 27, 2003
[Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study]T D Szucs, M Schwenkglenks, K Berger, et al.
Medizinische Klinik (Munich, Germany : 1983)|February 24, 2001
[Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study]T D Szucs, M Schwenkglenks, B Paschen, et al.
Oncology|September 17, 2011
Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemiaT D Szucs, P R Blank, M Schwenkglenks, et al.
Hematological Oncology|January 20, 2011
Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysisR Pettengell, M Schwenkglenks, P Bacon, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|October 25, 2008
Trends in influenza vaccination coverage rates in the United Kingdom over six seasons from 2001-2 to 2006-7P R Blank, A U Freiburghaus, M Schwenkglenks, et al.
Epidemiology and Infection|August 12, 2016
Estimating healthcare costs of acute gastroenteritis and human campylobacteriosis in SwitzerlandC Schmutz, D Mäusezahl, P J Bless, et al.
Breast Cancer Research and Treatment|June 10, 2016
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)K Matter-Walstra, T Ruhstaller, D Klingbiel, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 29, 2007
Simulation-based cost-utility analysis of population screening-based alendronate use in SwitzerlandM Schwenkglenks, K Lippuner
Medizinische Klinik (Munich, Germany : 1983)|February 11, 2000
[Economic evaluation of different treatment strategies in patients with stable angina pectoris or asymptomatic myocardial ischemia on basis of results from the Asymptomatic-Cardiac-Ischemia Pilot study (ACIP)]T D Szucs, M Schwenkglenks, W Rutishauser
Infection|September 22, 2009
Disparities in influenza vaccination coverage rates by target group in five European countries: trends over seven consecutive seasonsP R Blank, M Schwenkglenks, T D Szucs
Zeitschrift Fur Kardiologie|March 27, 2003
[Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study]T D Szucs, M Schwenkglenks, K Berger, et al.
Medizinische Klinik (Munich, Germany : 1983)|February 24, 2001
[Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study]T D Szucs, M Schwenkglenks, B Paschen, et al.
Oncology|September 17, 2011
Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemiaT D Szucs, P R Blank, M Schwenkglenks, et al.
Hematological Oncology|January 20, 2011
Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysisR Pettengell, M Schwenkglenks, P Bacon, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|October 25, 2008
Trends in influenza vaccination coverage rates in the United Kingdom over six seasons from 2001-2 to 2006-7P R Blank, A U Freiburghaus, M Schwenkglenks, et al.
Epidemiology and Infection|August 12, 2016
Estimating healthcare costs of acute gastroenteritis and human campylobacteriosis in SwitzerlandC Schmutz, D Mäusezahl, P J Bless, et al.
Breast Cancer Research and Treatment|June 10, 2016
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)K Matter-Walstra, T Ruhstaller, D Klingbiel, et al.
Pageof 3